LIFERIVER(SH:688317)2025-10-29 08:05Financial Performance - The company's operating revenue for the third quarter was ¥30,749,789.88, a decrease of 28.46% compared to the same period last year[3]. - The total profit for the third quarter was a loss of ¥18,338,008.92, with a year-to-date loss of ¥25,938,257.20[3]. - The net profit attributable to shareholders for the third quarter was a loss of ¥19,526,883.18, and the year-to-date loss was ¥29,377,855.95[3]. - The company experienced a 34.27% decline in operating revenue year-to-date, primarily due to decreased product sales and price reductions from centralized procurement policies[8]. - Total operating revenue for the first three quarters of 2025 was ¥90,432,870.13, a decrease of 34.2% compared to ¥137,579,847.20 in the same period of 2024[18]. - Net profit for the first three quarters of 2025 was a loss of ¥29,377,855.95, compared to a loss of ¥13,009,588.94 in 2024, representing a deterioration of 126.5%[19]. Research and Development - Research and development expenses totaled ¥12,727,608.42 for the quarter, accounting for 41.39% of operating revenue, an increase of 7.25 percentage points year-on-year[4]. - Research and development expenses for the first three quarters of 2025 were ¥42,058,199.29, an increase of 7.6% from ¥39,074,589.30 in 2024[18]. Assets and Liabilities - Total assets at the end of the reporting period were ¥3,721,101,815.28, a decrease of 1.82% from the end of the previous year[4]. - The total amount of current assets as of September 30, 2025, is approximately ¥2.94 billion, slightly increased from ¥2.93 billion in the previous year[14]. - Total assets amount to ¥3.72 billion, down from ¥3.79 billion in the previous year[14]. - Non-current assets total ¥783.24 million, a decrease from ¥854.34 million year-over-year[14]. - The total liabilities increased to ¥327,172,042.30 in 2025, compared to ¥153,063,328.61 in 2024, indicating a significant rise[16]. - The total equity attributable to shareholders decreased to ¥3,393,929,772.98 in 2025 from ¥3,636,886,762.51 in 2024, a decline of 6.7%[16]. Cash Flow - The net cash flow from operating activities for the year-to-date was ¥32,672,416.67, a decrease of 23.89% compared to the previous year[3]. - Cash inflow from operating activities totaled ¥172,091,272.35 in 2025, down 29.3% from ¥243,668,973.36 in 2024[22]. - The cash flow from sales of goods and services was ¥120,213,144.22 in 2025, down 24% from ¥158,023,714.74 in 2024[22]. - The net cash flow from operating activities was $32,672,416.67, a decrease of 24% compared to $42,926,358.23 in the previous period[23]. - The total cash outflow from operating activities was $139,418,855.68, compared to $200,742,615.13 previously, showing a reduction in operational cash outflows[23]. Shareholder Information - Total number of common shareholders at the end of the reporting period is 14,435[11]. - The largest shareholder, Shanghai Zhijiang Pharmaceutical Co., Ltd., holds 64,969,560 shares, representing 33.81% of total shares[11]. - The company has a total of 14,638,308 shares in its repurchase account, accounting for 7.62% of total shares[13]. - The company has no significant changes in the participation of major shareholders in margin trading or securities lending[13]. Other Financial Metrics - The weighted average return on net assets was -0.56%, an increase of 0.47 percentage points compared to the previous year[4]. - The basic earnings per share for the third quarter was -¥0.10, with a year-to-date figure of -¥0.16[4]. - The company reported non-recurring gains and losses totaling ¥4,477,565.75 for the quarter[7]. - The company reported a financial expense of -¥31,340,122.83 in 2025, a significant improvement from -¥67,266,345.27 in 2024[18]. - The company recorded a credit impairment loss of ¥1,168,467.86 in 2025, compared to a recovery of -¥215,377.15 in 2024[19]. - The company paid $57,114,359.51 in employee compensation, which is lower than $78,188,799.34 in the previous period[23]. - The company experienced a foreign exchange loss of -$9,676,055.88, compared to -$10,932,424.75 in the prior period[23]. - The company has not disclosed any new strategies or future outlook in the provided documents[12].